ALA — Arovella Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$82.63m
- AU$70.88m
- AU$0.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.16 | ||
| Price to Tang. Book | 7.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 186.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -54.16% | ||
| Return on Equity | -85.35% | ||
| Operating Margin | -1416.45% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.58 | 0.26 | 0.3 | 0.44 | 0.16 | n/a | n/a | -34.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.
Directors
- Paul Hopper CHM (64)
- Michael Baker CEO
- Joseph Ohayon CFO
- Carol Worth OTH
- Phillip Hains SEC
- David Simmonds NED
- Debora Barton NID
- Elizabeth Stoner NID (70)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 21st, 1999
- Public Since
- January 24th, 2002
- No. of Shareholders
- 4,959
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,059,388,529
- Address
- Osborne Park, U 12 L 1, 55 Howe St, PERTH, 3053
- Web
- https://www.arovella.com/
- Phone
- +61 398245254
- Auditors
- HLB Mann Judd
Upcoming Events for ALA
Arovella Therapeutics Ltd Extraordinary Shareholders Meeting
Full Year 2025 Arovella Therapeutics Ltd Earnings Release
Similar to ALA
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Arovella Therapeutics share price?
As of Today at 19:20 UTC, shares in Arovella Therapeutics are trading at AU$0.08. This share price information is delayed by 15 minutes.
How has the Arovella Therapeutics share price performed this year?
Shares in Arovella Therapeutics last closed at AU$0.08 and the price had moved by -32.17% over the past 365 days. In terms of relative price strength the Arovella Therapeutics share price has underperformed the ASX All Ordinaries Index by -33.21% over the past year.
What are the analyst and broker recommendations for Arovella Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Arovella Therapeutics dividend yield?
Arovella Therapeutics does not currently pay a dividend.
Does Arovella Therapeutics pay a dividend?
Arovella Therapeutics does not currently pay a dividend.
When does Arovella Therapeutics next pay dividends?
Arovella Therapeutics does not currently pay a dividend.
How do I buy Arovella Therapeutics shares?
To buy shares in Arovella Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arovella Therapeutics?
As of the previous close price of AU$0.08, shares in Arovella Therapeutics had a market capitalisation of AU$82.63m.
Where are Arovella Therapeutics shares listed?
Here are the trading details for Arovella Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ALA
What kind of share is Arovella Therapeutics?
Based on an overall assessment of its quality, value and momentum Arovella Therapeutics is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arovella Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Arovella Therapeutics is AU$0.14. That is 79.49% above the last closing price of AU$0.08.
Analysts covering Arovella Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.01 for the next financial year.
Find out moreWhat is the trend in the Arovella Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arovella Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -53.52%.
As of the last closing price of AU$0.08, shares in Arovella Therapeutics were trading -48.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arovella Therapeutics PE Ratio?
The Arovella Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arovella Therapeutics?
Arovella Therapeutics' management team is headed by:
- Paul Hopper - CHM
- Michael Baker - CEO
- Joseph Ohayon - CFO
- Carol Worth - OTH
- Phillip Hains - SEC
- David Simmonds - NED
- Debora Barton - NID
- Elizabeth Stoner - NID